Does Calm Health Partnership Signal a New Growth Path for LifeStance Health Group (LFST)?

• On October 28, 2025, Calm Health announced a partnership with LifeStance Health Group, allowing Calm Health users to access LifeStance's mental health services directly through the app when higher-acuity care is needed.
• This collaboration creates a streamlined connection from digital mental health screening to personalized in-person or virtual care, potentially lowering barriers for individuals seeking timely, evidence-based support.
• We'll examine how integrating Calm Health's digital platform with LifeStance's services could enhance patient acquisition and expand market access for the company.

We've found 20 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

LifeStance Health Group Investment Narrative Recap

To believe in LifeStance Health Group as a shareholder, you need confidence in the growing demand for mental health services in the US and the company’s ability to convert partnerships and technology investments into higher patient volumes and scalable revenue. The Calm Health partnership might help streamline patient acquisition, but its impact on LifeStance’s most pressing short-term challenge, clinician recruitment and retention, remains to be seen, and does not directly address immediate workforce pressures or margin risks from payer negotiations.

Among recent announcements, the upcoming Q3 2025 earnings release is most relevant, as it will be the first financial report after the Calm Health partnership was announced. Investors will likely watch for any early signs of increased visits or improvement in key financial metrics linked to digital referrals and expanded access.

However, on the flip side, investors should also be aware that persistent workforce shortages and recruitment challenges could...

Read the full narrative on LifeStance Health Group (it's free!)

LifeStance Health Group's narrative projects $2.0 billion in revenue and $111.7 million in earnings by 2028. This requires 14.6% yearly revenue growth and a $127.9 million increase in earnings from the current earnings of $-16.2 million.

Uncover how LifeStance Health Group's forecasts yield a $8.43 fair value, a 75% upside to its current price.

Exploring Other Perspectives

You can see three different fair value estimates for LifeStance Health from the Simply Wall St Community, ranging from US$5.89 to US$8.47 per share. Yet, clinician recruitment and retention continues to weigh on sentiment and could shape future growth, so consider how your outlook compares to these varied views.

Explore 3 other fair value estimates on LifeStance Health Group - why the stock might be worth just $5.89!

Build Your Own LifeStance Health Group Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your LifeStance Health Group research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free LifeStance Health Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate LifeStance Health Group's overall financial health at a glance.

Curious About Other Options?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• Outshine the giants: these 26 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com